Literature DB >> 26577687

Quantitative Evaluation of Tumour--Associated Tissue Eosinophilia and Cyclo-oxegenase-2 Gene in Oral Cancer Patients with Assessment of Long Term Outcomes.

N Rakesh1, Asha Iyengar2, Kuhu Majumdar3, G S Vidya4, S S Shantha Kumar5.   

Abstract

Various histopathological parameters have been extensively studied for prognostication of oral cancer but the focus is now getting diverted towards the role of inflammatory mediators in cancer progression. The present study was undertaken to evaluate two such components of the inflammatory milieu, tumor-associated tissue eosinophilia (TATE) as well as Cyclo-oxygenase-2 (COX-2) gene expression, quantitatively in oral squamous cell carcinoma (OSCC) patients in relation to treatment outcomes and patterns of recurrence. A total of forty five patients with primary OSCC matching our inclusion criteria were selected for the study and followed up over a five year period. TATE was evaluated from the invasive front of the tumor using Haematoxylin and eosin (H & E) stained sections of histopathological specimens and graded as mild, moderate or intense. COX-2 gene expression was obtained from specimens using the reverse transcriptase--polymerase chain reaction (RT-PCR) method. A statistically significant association was observed between degree of TATE and locoregional recurrence (P < 0.001). The expression of COX-2 gene ranged from 0.4326 to 0.9998 and a higher mean COX-2 score was recorded in samples with intense degree of TATE followed by moderate and mild TATE. (P < 0.001). Using the t-test, the difference in mean COX-2 was found to be statistically significant (P < 0.001) between patients who developed locoregional recurrence and those who did not. The analysis of TATE may provide an indication of future recurrence at the time of diagnosis of OSCC. Also, the increased expression of COX-2 gene in OSCC strongly suggests its possible use as a chemopreventive/chemotherapeutic target.

Entities:  

Keywords:  COX-2; Cyclooxygenase-2; Locoregional recurrence; Oral squamous cell carcinoma; TATE; Tumour associated tissue eosinophilia

Mesh:

Substances:

Year:  2015        PMID: 26577687     DOI: 10.1007/s12253-015-0016-7

Source DB:  PubMed          Journal:  Pathol Oncol Res        ISSN: 1219-4956            Impact factor:   3.201


  40 in total

1.  Eosinophils may predict occult lymph node metastasis in early oral cancer.

Authors:  D T Oliveira; T P Biassi; S E S Faustino; A L Carvalho; G Landman; L P Kowalski
Journal:  Clin Oral Investig       Date:  2011-12-14       Impact factor: 3.573

2.  Clinicopathological parameters, recurrence, locoregional and distant metastasis in 115 T1-T2 oral squamous cell carcinoma patients.

Authors:  Waseem Jerjes; Tahwinder Upile; Aviva Petrie; Andrew Riskalla; Zaid Hamdoon; Michael Vourvachis; Kostas Karavidas; Amrita Jay; Ann Sandison; Gareth J Thomas; Nicholas Kalavrezos; Colin Hopper
Journal:  Head Neck Oncol       Date:  2010-04-20

Review 3.  Global epidemiology of oral and oropharyngeal cancer.

Authors:  Saman Warnakulasuriya
Journal:  Oral Oncol       Date:  2008-09-18       Impact factor: 5.337

4.  An eosinophil-dependent mechanism for the antitumor effect of interleukin-4.

Authors:  R I Tepper; R L Coffman; P Leder
Journal:  Science       Date:  1992-07-24       Impact factor: 47.728

5.  Fluorinated COX-2 inhibitors as agents in PET imaging of inflammation and cancer.

Authors:  Md Jashim Uddin; Brenda C Crews; Kebreab Ghebreselasie; Imran Huda; Philip J Kingsley; Mohammad Sib Ansari; Mohammed N Tantawy; Jeffery Reese; Lawrence J Marnett
Journal:  Cancer Prev Res (Phila)       Date:  2011-09-07

6.  Prognostic significance of stromal eosinophilic infiltration in cancer of the larynx.

Authors:  Ibrahim Ercan; Burak Cakir; Tülay Başak; Tuncay Ozdemir; Ibrahim Sayin; Suat Turgut
Journal:  Otolaryngol Head Neck Surg       Date:  2005-06       Impact factor: 3.497

7.  Prognostic factors for well-differentiated squamous cell carcinoma in the oral cavity with emphasis on immunohistochemical evaluation.

Authors:  K Horiuchi; K Mishima; M Ohsawa; M Sugimura; K Aozasa
Journal:  J Surg Oncol       Date:  1993-06       Impact factor: 3.454

8.  Influence of pathological tumour variables on long-term survival in resectable gastric cancer.

Authors:  A Cuschieri; I C Talbot; S Weeden
Journal:  Br J Cancer       Date:  2002-03-04       Impact factor: 7.640

Review 9.  Molecular changes in invasive front of oral cancer.

Authors:  Mohit Sharma; Parul Sah; Sonal Soi Sharma; Raghu Radhakrishnan
Journal:  J Oral Maxillofac Pathol       Date:  2013-05

Review 10.  Diagnostic aids in the screening of oral cancer.

Authors:  Stefano Fedele
Journal:  Head Neck Oncol       Date:  2009-01-30
View more
  4 in total

1.  Differential Expression of Potential Biomarkers of Oral Squamous Cell Carcinoma Development.

Authors:  Paola Fernandes Pansini; Isabella Bittencourt do Valle; Thabata Coeli Dias Damasceno; Priscila Marinho de Abreu; Anna Clara Gregório Có; Rossana Verónica Mendoza López; Jeferson Lenzi; Ricardo Mai Rocha; Evandro Duccini Souza; Maria Paula Curado; Hisham Mehanna; Paul Nankivell; José Roberto Vasconcelos de Podestá; Sandra Ventorin von Zeidler
Journal:  Head Neck Pathol       Date:  2021-04-11

2.  Quantitative analysis of tumor-associated tissue eosinophils and tumor-associated blood eosinophils in oral squamous cell carcinoma.

Authors:  Safia Siddiqui; Rohit Jaiswal; Ghulam Sarwar Hashmi
Journal:  J Oral Maxillofac Pathol       Date:  2020-05-08

3.  Isoform-Specific Role of Akt in Oral Squamous Cell Carcinoma.

Authors:  Nand Kishor Roy; Javadi Monisha; Ganesan Padmavathi; H Lalhruaitluanga; Nachimuthu Senthil Kumar; Anuj Kumar Singh; Devivasha Bordoloi; Munindra Narayan Baruah; Gazi Naseem Ahmed; Imliwati Longkumar; Frank Arfuso; Alan Prem Kumar; Ajaikumar B Kunnumakkara
Journal:  Biomolecules       Date:  2019-06-27

Review 4.  Role of Cyclooxygenase-2 in Head and Neck Tumorigenesis.

Authors:  Ellen Frejborg; Tuula Salo; Abdelhakim Salem
Journal:  Int J Mol Sci       Date:  2020-12-03       Impact factor: 5.923

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.